Literature DB >> 27940599

Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Jennifer N Rauch1, Steven H Olson1, Jason E Gestwicki1.   

Abstract

Tau aggregation is linked to multiple neurodegenerative disorders that are collectively termed tauopathies. Small molecules are powerful probes of the aggregation process, helping to reveal the key steps and serving as diagnostics and reporters. Moreover, some of these small molecules may have potential as therapeutics. This review details how small molecules and chemical biology have helped to elucidate the mechanisms of tau aggregation and how they are being used to detect and prevent tau aggregation. In addition, we comment on how new insights into tau prions are changing the approach to small molecule discovery.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27940599      PMCID: PMC5495054          DOI: 10.1101/cshperspect.a024034

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  114 in total

1.  Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.

Authors:  Andrew Lockhart; Liang Ye; Duncan B Judd; Andy T Merritt; Peter N Lowe; Jennifer L Morgenstern; Guizhu Hong; Antony D Gee; John Brown
Journal:  J Biol Chem       Date:  2004-12-21       Impact factor: 5.157

2.  Thioflavin S fluorescent and Congo red anisotropic stainings in the histologic demonstration of amyloid.

Authors:  G Kelényi
Journal:  Acta Neuropathol       Date:  1967-02-03       Impact factor: 17.088

3.  Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure.

Authors:  O Schweers; E Schönbrunn-Hanebeck; A Marx; E Mandelkow
Journal:  J Biol Chem       Date:  1994-09-30       Impact factor: 5.157

4.  Structural determinants of Tau aggregation inhibitor potency.

Authors:  Kelsey N Schafer; Katryna Cisek; Carol J Huseby; Edward Chang; Jeff Kuret
Journal:  J Biol Chem       Date:  2013-09-26       Impact factor: 5.157

5.  Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.

Authors:  Claude M Wischik; Roger T Staff; Damon J Wischik; Peter Bentham; Alison D Murray; John M D Storey; Karin A Kook; Charles R Harrington
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 6.  Tau-aggregation inhibitor therapy for Alzheimer's disease.

Authors:  Claude M Wischik; Charles R Harrington; John M D Storey
Journal:  Biochem Pharmacol       Date:  2013-12-19       Impact factor: 5.858

7.  FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions.

Authors:  Benjamin Combs; T Chris Gamblin
Journal:  Biochemistry       Date:  2012-10-18       Impact factor: 3.162

8.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

Review 9.  Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

Authors:  Diane P Hanger; Brian H Anderton; Wendy Noble
Journal:  Trends Mol Med       Date:  2009-02-24       Impact factor: 11.951

10.  Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.

Authors:  Michelle T Fodero-Tavoletti; Shozo Furumoto; Leanne Taylor; Catriona A McLean; Rachel S Mulligan; Ian Birchall; Ryuichi Harada; Colin L Masters; Kazuhiko Yanai; Yukitsuka Kudo; Christopher C Rowe; Nobuyuki Okamura; Victor L Villemagne
Journal:  Alzheimers Res Ther       Date:  2014-02-26       Impact factor: 6.982

View more
  4 in total

Review 1.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

Review 2.  The structure and phase of tau: from monomer to amyloid filament.

Authors:  Yifan Zeng; Jing Yang; Bailing Zhang; Meng Gao; Zhengding Su; Yongqi Huang
Journal:  Cell Mol Life Sci       Date:  2020-10-19       Impact factor: 9.261

Review 3.  The Structure Biology of Tau and Clue for Aggregation Inhibitor Design.

Authors:  Dan Wang; Xianlong Huang; Lu Yan; Luoqi Zhou; Chang Yan; Jinhu Wu; Zhengding Su; Yongqi Huang
Journal:  Protein J       Date:  2021-08-17       Impact factor: 2.371

4.  X-ray multiscale 3D neuroimaging to quantify cellular aging and neurodegeneration postmortem in a model of Alzheimer's disease.

Authors:  Giuseppe Battaglia; Paola Coan; Giacomo E Barbone; Alberto Bravin; Alberto Mittone; Alexandra Pacureanu; Giada Mascio; Paola Di Pietro; Markus J Kraiger; Marina Eckermann; Mariele Romano; Martin Hrabě de Angelis; Peter Cloetens; Valeria Bruno
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-19       Impact factor: 10.057

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.